Comparative Pharmacology
Head-to-head clinical analysis: ILOPERIDONE versus VERSACLOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOPERIDONE versus VERSACLOZ.
ILOPERIDONE vs VERSACLOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iloperidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors; also moderate affinity for D3, D4, 5-HT6, 5-HT7, and α1-adrenergic receptors; low affinity for H1, 5-HT1A, and α2-adrenergic receptors; no affinity for M1 muscarinic receptors.
Clozapine is an atypical antipsychotic that binds to dopamine D4 and serotonin 5-HT2A receptors with high affinity, and also to D1, D2, D3, D5, 5-HT1A, 5-HT1C, 5-HT3, 5-HT6, 5-HT7, alpha-adrenergic, histamine H1, and muscarinic M1-M5 receptors.
1-2 mg orally twice daily; target dose 6-12 mg/day; maximum 12 mg/day
Initial: 12.5 mg orally once or twice daily; titrate by 25-50 mg/day to target dose of 300-450 mg/day divided, with maximum 900 mg/day.
None Documented
None Documented
Clinical Note
moderateIloperidone + Levofloxacin
"Iloperidone may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateIloperidone + Norfloxacin
"Iloperidone may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateIloperidone + Gemifloxacin
"Iloperidone may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateIloperidone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Iloperidone."
Terminal elimination half-life 18 hours in extensive CYP2D6 metabolizers, 33 hours in poor metabolizers; clinical context: steady-state reached in ~5-7 days.
Terminal elimination half-life ~12 hours (range 6-33 hours); steady-state achieved within 7-10 days; requires gradual dose titration to mitigate seizure risk.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; approximately 7% excreted unchanged in urine and 18% in feces; total renal elimination of metabolites ~25%, fecal ~60%.
Renal: ~50% (30% as unchanged drug, rest as metabolites); fecal: ~30% (via bile); minor biliary elimination.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic